UK Markets closed

Hyloris Pharmaceuticals SA (HYL.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
15.25-0.05 (-0.33%)
At close: 05:35PM CET

Hyloris Pharmaceuticals SA

Boulevard Gustave Kleyer 17
Liège 4000
Belgium
32 4 346 02 07
http://www.hyloris.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Stijn Van RompayCo-Founder & CEON/AN/AN/A
Mr. Thomas JacobsenCo-Founder & Exec. DirectorN/AN/AN/A
Mr. Patrick JeanmartChief Financial OfficerN/AN/A1972
Dr. Dietmar Aichhorn Ph.D.Chief Operating OfficerN/AN/AN/A
Ms. Marieke VermeerschVP Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Koenraad Van Der ElstChief Legal OfficerN/AN/A1962
Mr. Maurizio PassanisiChief Clinical OfficerN/AN/AN/A
Mr. Ed MaloneyChief Bus. Devel. OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hyloris Pharmaceuticals SA manufactures pharmaceutical products. The company offers cardiovascular products for atrial fibrillation, congestive heart failure, and coronary heart disease; intravenous ready-to-use and oral liquid formulations; and topical gel and cream products. Hyloris Pharmaceuticals SA was founded in 2013 and is based in Liege, Belgium.

Corporate governance

Hyloris Pharmaceuticals SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.